Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as eff ective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma.
Introduction
The 2014 revision of the Global Initiative for Asthma (GINA) guidelines recommends that patients with asthma should fi rst be assessed for the level of asthma control and then treatment should be planned accordingly. 1 For patients whose asthma is not controlled by low-dose inhaled corticosteroids, guidelines recommend a combination of low-dose inhaled corticosteroids and a longacting β 2 agonist plus a rapidacting β 2 agonist for symptom relief, or treatment with inhaled corticosteroids and rapid-acting longacting β 2 agonist both regularly and for symptom relief. This approach, called same maintenance and reliever therapy (SMART), achieves similar levels of asthma control as inhaled corticosteroids and longacting β 2 agonists plus a rapid-acting β 2 agonist for symptom relief but more eff ective reduction of exacerbations in patients with moderate to severe asthma. [2] [3] [4] [5] [6] [7] [8] [9] [10] The symptom-driven use of an inhaled corticosteroid with a shortacting β 2 agonist or an inhaled corticosteroid and longacting β 2 agonist combination in the absence of any regular maintenance treatment are viewed as eff ective alternatives to regular inhaled corticosteroid plus asneeded shortacting β 2 agonist in patients with intermittent or mild asthma. 11, 12 In patients with mild persistent asthma that is controlled by regular low-dose inhaled corticosteroid, the as-needed combination of beclometasone and the short-acting β 2 agonist salbutamol with no regular treatment is non-inferior to regular low-dose beclometasone plus as-needed salbutamol. 13 The rationale for use of a symptom-driven approach is that it allows titration of both the inhaled corticosteroid and the longacting β 2 agonist according to the patient's needs, it is associated with lower cumulative exposure to both bronchodilators and inhaled corticosteroids, and it might reduce the eff ect of low adherence to regular treatment that frequently occurs in real life. 11, 12, 14 Additionally, treatment with a steroid together with a bronchodilator for symptom relief could be more eff ective than a bronchodilator alone, since it might reverse not only bronchoconstriction but also the transient acute airway infl ammation [15] [16] [17] [18] associated with the development of symptoms. 11, [19] [20] [21] [22] Therefore, it might improve asthma control and reduce the need for regular treatment.
No previous study has investigated whether moderate asthmatics-ie, patients whose asthma is not controlled by low-dose inhaled corticosteroids but is adequately controlled by an inhaled corticosteroid and longacting β 2 agonist combination-can be just as well controlled by a symptom-driven inhaled corticosteroid and longacting β 2 agonist combination therapy in the absence of regular maintenance treatment.
In this 1-year study, we investigated whether treatment failure could be prevented in patients with moderate asthma receiving regular placebo plus as-needed combination budesonide and formoterol versus regular treatment with budesonide and formoterol plus asneeded terbutaline.
Methods

Study design and participants
This trial was a multicentre, randomised, placebocontrolled, double-blind, parallel-group study (appendix p 9). The study population consisted of adults (18-65 years of age) with moderate persistent asthma, according to 2006 GINA guidelines, 23 whose symptoms were either not controlled by low-dose inhaled corticosteroids (≤500 μg beclometasone per day or equivalent; 594 [73%] of 817 enrolled patients in the intention-to-treat population) or controlled by a fi xed combination of lowdose inhaled corticosteroid and longacting β 2 agonist twice daily during the 2 months before the study (223 [27%] of 817 patients in the intention-to-treat population). Patients were recruited from outpatient clinics of secondary and tertiary referral hospitals and university centres. Asthma was judged to be not adequately controlled with low-dose inhaled corticosteroids if patients reported more than two daytime symptoms per week, more than two occasions per week when they needed rescue treatment, any nocturnal symptoms or awakening, any limitation of activities, and use of oral corticosteroids in the month before enrolment. By contrast, asthma was regarded as adequately controlled in patients who had initiated low-dose inhaled corticosteroid and longacting β 2 agonist combination treatment in the past year because asthma was not controlled by low-dose inhaled corticosteroid, and if in the 2 months before the study they reported a maximum of two daytime symptoms in a week, a maximum of two occasions per week when they needed rescue treatment, no nocturnal symptoms or awakening, no limitation of activities, and no use of oral corticosteroids. The main exclusion criteria were: inability to undergo pulmonary function testing; moderately severe asthma associated with reduced lung function; history of near-fatal asthma, admission to the intensive care unit because of asthma, or both; three or more courses of oral corticosteroids or hospital admissions for asthma during the previous year; diagnosis of chronic obstructive pulmonary disease as defi ned by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks; current smoker or recent (<1 year) ex-smoker, defi ned as smoking at least ten pack-years; history of, or existing evidence of, heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias; and diabetes mellitus. Appendix p 6 provides further details of inclusion and exclusion criteria.
The protocol was approved by the institutional review board for each centre, and all participants provided written informed consent. The study was done in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
Procedures
Between April 20, 2009 and March 31, 2012, we recruited and enrolled 1010 eligible patients with moderate asthma. The patients entered a 6-week run-in period, during which they received an open-label combination of inhaled 160 μg budesonide and 4·5 μg formoterol twice daily, plus as-needed inhaled 500 μg terbutaline. At the end of the run-in, 866 eligible patients with controlled asthma during the fi nal 14 days of the run-in were randomly allocated in a 1:1 ratio to receive either twicedaily placebo plus as-needed inhaled 160 μg budesonide and 4·5 μg formoterol combination (as-needed budesonide and formoterol) or twice daily 160 μg budesonide and 4·5 μg formoterol combination plus asneeded inhaled 500 μg terbutaline (regular budesonide and formoterol). Patients were not given a written plan of action to guide the as-needed use of study drugs but were merely verbally instructed to use them any time they were needed for relief of symptoms. Patients were not given oral corticosteroids or additional inhaled See Online for appendix cortico steroids to keep at home for self-administration in case of asthma deterioration, but were instructed, according to current clinical practice, to seek medical attention or investigator contact (unscheduled visits) in case of uncontrolled clinical condition. At the end of 1 year of treatment, patients underwent 6 weeks of follow-up open-label SMART therapy with 160 μg budesonide and 4·5 μg formoterol with the aim to assess whether maximising treatment would modify the level of asthma control recorded at the end of the study (appendix p 9). Up to eight additional as-needed inhalations of rescue medication (either budesonide and formoterol inhaled combination or inhaled salbutamol) per day were allowed for the entire study duration. No other antiasthma drug was allowed. All drugs were prepared and given by the dry-powder inhaler Turbohaler (AstraZeneca S.p.a., Basiglio, Milan, Italy). Clinic visits took place at the beginning (visit 1) and end (visit 2) of the run-in period and thereafter on study weeks 4, 12, 20, 28, 36, 44, 52 (visit 9: end of treatment period) and 58 (visit 10: end of follow-up period) for a total of ten visits. Treatment compliance was assessed by the clinical investigator at each visit by asking the patients to return study drug devices and diary cards. Diary cards were reviewed and correct use of the device was assessed at each visit. Compliance to treatment was checked by counting the remaining doses (on the dose counter within the inhaler) in each returned dry powder inhaler at the end of the study period (visit 9) and reporting the number in the case report form. Compliance to treatment was expressed as the percentage of the expected number of doses actually taken in the previous 8 weeks.
As specifi ed in the protocol, the investigators or the family doctor could give patients additional medication to treat worsening asthma, including additional open-label courses of inhaled twice-daily corticosteroids or oral or systemic corticosteroids. Patients were also recom mended to stop study medication during exacer bations and restart afterwards. Investigators were asked to record in the case report form the treatments that the patients received for the exacerbations. Patients were not withdrawn from the study after an exacerbation, unless such a decision was made by the patient, family doctor, or investigator.
Randomisation and masking
Patients were randomly assigned to a treatment group according to a list prepared with the use of a randomnumber generator and a balanced permuted block design (block size of 4), stratifi ed by centre.
Investigators and patients were masked to treatment assignment. Dry powder inhaler devices were identical in shape and used in all groups to ensure a double-blind design. The powder was odourless. The inhalation devices containing regular treatment (budesonide and formoterol combination or placebo) were white, whereas those for as-needed treatment (terbutaline or combined budesonide and formoterol) were yellow.
A package insert written in Italian containing the instructions for use was included in each test treatment inhaler. Patients were instructed to take one inhalation in the morning and one inhalation in the evening from the white device, and one or more inhalation when needed for symptom relief from the yellow device. Patients were individually instructed by the investigators to use the dry powder inhalers with the support of the package insert.
Outcomes
The primary outcome of the study was the time to treatment failure measured at 1 year. The power of the study was based on the rate of treatment failure at 1 year. Treatment failure was defi ned as the occurrence of one of the following: admission to hospital, unscheduled medical visits for asthma, use of systemic corticosteroids or openlabel use of inhaled corticosteroids for asthma prescribed by a doctor, two nocturnal awakenings on 2 consecutive days, four or more additional puff s of as-needed medication per day compared with baseline on 2 consecutive days, patient refusal to continue because of dissatisfaction with treatment, or if treatment was stopped by the physician for safety reasons. Secondary outcomes were: time to treatment failure measured at other timepoints during the treatment period, time to dropout, use of rescue medication, asthma control, quality of life, daily morning and evening peak expiratory fl ow (measured by the patient at home); pre-bronchodilator forced vital capacity; ratio of forced expiratory volume in 1 s to vital capacity; ratio of forced expiratory volume in 1 s to forced vital capacity; post-bronchodilator forced expiratory volume in 1 s; asthma symptom scores; rescue medications; Asthma Control Questionnaire; 24 and Asthma-Related Quality of Life Questionnaire. 25 Secondary safety outcomes were adverse events and morning serum cortisol (appendix p 4).
Statistical analysis
We estimated that the proportion of patients in the regular budesonide and formoterol group with treatment failure at 1 year would be 35%, and we judged a non-inferiority margin of 9% at 1 year to be clinically acceptable, based on an estimated eff ect size of 17%. 7, 26 A total of 355 treatment failures (in patients with at least one treatment failure) were needed to test the non-inferiority (one-sided test at 0·025 signifi cance) of the time to treatment failure of the as-needed budesonide and formoterol therapy group versus the regular budesonide and formoterol therapy group, with a power of at least 80%. A total of 860 evaluable patients (430 in each treatment group) were needed to satisfy the aforementioned hypothesis.
We used Kaplan-Meier estimates to assess the time to treatment failure and the probability of patients with no treatment failure at 1 year. We also analysed time to treatment failure with a Cox proportional hazards regression model, in which treatment was the only term included in the model.
Methods for the sensitivity analyses of the primary outcome, and ANCOVA models for secondary quantitative endpoints, are described in appendix pp 4-5. We did a post-hoc analysis to assess the eff ects of baseline risk factors or covariates on the probability of treatment failure by means of a logistic analysis. The primary endpoint was assessed in both the intention-to-treat and per-protocol population. The intention-to-treat population included all randomly assigned patients who received at least one dose of the study drug and who had at least one available post-baseline effi cacy evaluation. The perprotocol population comprised all patients from the intention-to-treat population without any major protocol deviations. All secondary endpoints were analysed in the intention-to-treat population. Safety outcomes were assessed in the safety population-ie, the number of patients who actually received treatment. Data are n (%) or mean (SD; number of patients), unless otherwise indicated. FEV 1 =forced expiratory volume in 1 s. FVC=forced vital capacity. ACQ=Asthma Control Questionnaire. AQLQ=Asthma-Related Quality of Life Questionnaire. *Daytime asthma symptoms were assessed in the evening on a scale ranging from 0 (no symptoms) to 4 (symptoms for most of the day that aff ected normal daily activities), whereas night-time symptoms were assessed in the morning on a scale ranging from 0 (no symptoms during the night) to 4 (symptoms so severe that they did not allow the patient to sleep at all). All statistical analyses and data processing were done using Statistical Analysis Systems (SAS) software, version 9.2, on a Windows 7 operating system. This trial is registered with ClinicalTrials.gov, number NCT00849095.
Role of the funding source
Data were collected by the clinical investigators, analysed by CROS NT (Verona, Italy), and discussed by the clinical investigators. AstraZeneca, who donated the drugs, had no role in study design, data collection or analyses, or in drafting the report, nor were they informed of the results of the study. The fi rst author and study coordinator (AP), the study manager (BM), and the corresponding author (LMF) oversaw all the data analyses. The fi rst author and the corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
In total, 1010 patients were screened and entered the 6-week run-in period, and 866 eligible patients were randomly assigned to the two treatment groups (424 to the as-needed budesonide and formoterol group and 442 to the regular budesonide and formoterol group (fi gure 1). The 18 patient diff erence in allocation between treatment groups was because of uncompleted randomisation blocks opened by sites during the study. Because some patients withdrew from the study before treatment was started, the number of patients who actually received treatment (the safety population) was 419 in the as-needed treatment group and 437 in the regular treatment group. The intention-to-treat population comprised 394 patients in the as-needed group and 423 in the regular treatment group, and the per-protocol population, which excluded two patients with major protocol violations, included 393 and 422 patients, respectively. As fi gure 1 shows, 249 patients in the as-needed budesonide and formoterol group and 304 patients in the regular budesonide and formoterol group completed the study.
The treatment groups were well matched in demographic and clinical characteristics at baseline (table 1) . Mean compliance to treatment at the end of the study period (visit 9) was 85% (SD 27) in the as-needed budesonide and formoterol group and 83% (26) in the regular budesonide and formoterol group.
Compared with regular budesonide and formoterol therapy, patients in the as-needed treatment group had shorter time to fi rst treatment failure (table 2, fi gure 2) and a higher probability of treatment failure (KaplanMeier estimates 53·6% for regular treatment vs 64·0% for as-needed treatment; diff erence 10·3% [95% CI 3·2-17·4], predefi ned non-inferiority limit 9%; p=0·0022) at 1 year (table 2, fi gure 2) in the intention-to-treat population analysis. The hazard ratio between the two groups was 1·49 (95% CI 1·19-1·87). The curves of log(-log[survival]) versus log of survival time by intentionto-treat analysis show that the two curves for the two groups were parallel, which confi rmed the proportional hazards assumption. We also tested the correlation of the scaled Schoenfeld residuals on functions of time for both the intention-to-treat and per-protocol population. The Pearson correlation was not statistically signifi cant (Pearson correlation coeffi cient 0·02814, p=0·5302), indicating no violation of the proportional hazards assumption.
The cumulative number of patients who had at least one treatment failure during the 1-year study period was 170 (43·1%) of 394 in the as-needed budesonide and formoterol group and 139 (32·9%) of 423 in the regular budesonide and formoterol group (table 2) ; thus, this The results reported in the per-protocol analysis were consistent with those in the intention-to-treat population (appendix p 7). The pre-planned sensitivity analyses, which treated dropouts as treatment failures (appendix p 10), confi rmed the robustness of the results of the primary outcome. The most common reason for treatment failure was two nocturnal awakenings on two consecutive days (82 patients in the as-needed budesonide and formoterol group and 44 in the regular budesonide and formoterol group). This outcome was the only component of the composite primary outcome that diff ered signifi cantly between groups (p<0·0001) (table 3). The mean percentage of days with nocturnal awakenings was 16·17% (SD 23·94) in the as-needed budesonide and formoterol group and 7·94% (16·07) in the regular budesonide and formoterol group. Female sex in the as-needed budesonide and formoterol group, smoking habits overall and in the as-needed budesonide and formoterol group, and baseline Asthma Control Questionnaire score overall and in both groups, were the factors signifi cantly associated with increased risk of treatment failure (fi gure 3).
The time to dropout, representing the time until at least 25% of the patients (ie, the fi rst quartile) dropped out of the study, was shorter in the as-needed budesonide and formoterol group (28 days) than in the regular treatment group (48 days; p=0·009 between groups in the log-rank test). Appendix p 11 shows the Kaplan-Meier plot for the time to dropout in the intention-to-treat population. The cumulative number of patients who dropped out at the end of the randomised treatment phase was 133 (33·7%) of 394 patients in the as-needed budesonide and formoterol group and 108 (25·5%) of 423 in the regular budesonide and formoterol group (Kaplan-Meier estimates 34·0% vs 25·9%; p=0·009). Table 4 shows the results of the other secondary outcomes. From baseline to the end of treatment in the randomised phase of the study, signifi cant diff erences were recorded between the two groups, in favour of regular budesonide and formoterol therapy.
After the follow-up period with open-label SMART budesonide and formoterol therapy (appendix p 8) only morning peak expiratory fl ow (p=0·02), number of puff s of rescue medication (p=0·012), and percentage of days without use of rescue medication (p=0·004) still diff ered signifi cantly between the groups in favour of regular budesonide and formoterol therapy.
Patients on as-needed budesonide and formoterol combination treatment used signifi cantly more rescue medications, and the diff erence, albeit small, remained signifi cant even at the end of follow-up (table 4; appendix p 8). Unsurprisingly, the estimated cumulative dose of budesonide (116·8 vs 24·5 mg per year) and formoterol (3·2 mg vs 0·69 mg per year) was larger in patients treated with regular budesonide and formoterol combination than in those who received the treatment as needed.
Apart from the number of patients with oropharyngeal pain, the frequency of treatment-emergent adverse events did not diff er between the two groups (p=0·363 ;  table 5 ). Similarly, the number of patients with adverse reactions also did not diff er between the groups (p=0·815). Worsening of asthma was the most common treatment-emergent adverse event: it was recorded in 48 patients (12%) in the as-needed group and 40 (9%) in the regular treatment group (table 5) . From baseline to the end of the treatment period, morning serum cortisol showed no evidence of adrenal suppression in either group (data not shown).
Discussion
In this 1-year, randomised, double-blind, clinical trial in patients with moderate asthma, as-needed budesonide and formoterol was inferior to regular budesonide and formoterol combination treatment plus as-needed terbutaline in preventing treatment failure. Our results confi rm that the regular longacting β 2 agonist combination treatment recommended in guidelines is eff ective for patients whose asthma is not adequately controlled by regular inhaled corticosteroids (panel). 1 Nocturnal awakenings were the only component of treatment failure that was not protected by the as-needed budesonide and formoterol therapy, most likely either because of absence of protection off ered by the regular treatment or because of no prompt reversal of nocturnal symptoms by the as-needed treatment. The overall increased number of nocturnal awakenings in the asneeded budesonide and formoterol group was 38 episodes of nocturnal awakening in 2 consecutive Data are n (%). Table 3 : Reasons for treatment failure in the intention-to-treat population nights in 1 year for the 394 patients in the intention-totreat population-ie, an average increased risk of one episode of nocturnal awakening in two consecutive nights per patient in 10 years, which might be regarded as of low clinical relevance. The other diff erence between the two treatments was the higher rate of dropout from the study in patients on as-needed budesonide and formoterol treatment. The dropout was reported to be not related to effi cacy or safety reasons, but mainly to withdrawal of consent (11·5% vs 14·6%) and other logistical reasons (5·4% vs 8·0%). In a young and actively working population, it is not surprising that the willingness (and possibility) to follow the strict rules and timing for multiple visits of a randomised controlled trial for a whole year might be too demanding, and thus patients withdrew their consent (the main reason for dropout), especially in a non-sponsored study like this one, in which patients receive no payment or expense reimbursement for their participation. However, the diff erence in dropout rate between the two groups (5·4% vs 8·0%) further suggests inferiority of the as-needed treatment.
The results of the sensitivity analyses that took into account the study dropouts confi rmed the results of the primary analysis, excluding that they might have been aff ected by the diff erent dropout rates.
Because of the characteristics of the population analysed-ie, patients with moderate asthma well controlled by the regular inhaled corticosteroid and longacting β 2 agonist combination and thus not at high risk of exacerbations-the primary outcome of our study was time to treatment failure. Indeed, only 117 severe exacerbations (defi ned as treatment with steroids and/or admission to the emergency room or hospital 7 ) occurred in 817 patients during the 1-year study (0·143 per patient per year): 53 (none of whom were admitted to hospital) in the as-needed budesonide and formoterol group (0·135 per patient per year) and 64 (four admitted to hospital) in the regular budesonide and formoterol group (0·151 per patient per year). Therefore, both therapies were associated with a very low incidence of severe exacerbations, possibly because they were both eff ective in controlling exacerbations.
Poor adherence to the regular treatment might have reduced the diff erence in medication use between the two groups, thereby contributing to the small diff erences in outcomes at the end of the study. In fact, Patel and colleagues 8 recently reported that adherence to regular treatment is lower than to SMART treatment and decreases progressively over 6 and 12 months, suggesting that poor adherence to regular maintenance treatment might have aff ected the small diff erences in outcomes that we reported Numbers for each outcome are the number of patients (n) in whom the outcome was assessed; mean change values are expressed as changes from baseline to the end of randomised treatment (week 52). All measurements were done pre-bronchodilator, unless otherwise indicated. Morning PEF, evening PEF, asthma symptoms score, % of days without symptoms, rescue medication, and % of days without rescue medication are analysed excluding from the analysis the diary card measurements in which the patients entered less than 75% data in the fi nal 2 weeks before the visit (ie, <10 days over the 2 weeks preceding a study visit). n=number of patients. PEF=peak expiratory fl ow. FEV 1 =forced expiratory volume in 1 s. FVC=forced vital capacity. ACQ=Asthma Control Questionnaire. AQLQ=Asthma-Related Quality of Life Questionnaire. *In the 2 weeks preceding the medical visit. †Measured at sites. Table 4 : Secondary outcomes in the intention-to-treat population in our study. However, the diff erences in our study probably represent what would happen in real life with use of the two diff erent treatment strategies that we compared. After the 1-year randomised treatment, both groups of patients received 6 weeks of SMART treatment with both maintenance and reliever budesonide and formoterol therapy to reverse uncontrolled components of asthma, if any. Both groups improved clinically and in most measurements of lung function (forced vital capacity, forced expiratory volume in 1 s, and peak expiratory fl ow) taken in the clinic. These values returned to baseline, which suggests that no irreversible decline in lung function had occurred. However, morning peak expiratory fl ow measured by the patient at home decreased signifi cantly in the as-needed budesonide and formoterol group and did not return to baseline after 6 weeks of SMART treatment. The reasons for the discrepancy between measurements of lung function made by the patient and in the clinic remain unclear. 27 Although the decrease in morning peak expiratory fl ow might suggest that the as-needed budesonide and formoterol therapy could be associated with a decline in pulmonary function that was not reversible even after 6 weeks of SMART treatment with budesonide and formoterol, the fact that such a decline was not recorded in clinically assessed peak expiratory fl ow, forced vital capacity, and forced expiratory volume in 1 s is reassuring.
The use of rescue medication and the percentage of days without the use of rescue medication remained signifi cantly diff erent between groups at the end of the 6-week SMART follow-up therapy, which suggests that long-term use of as-needed therapy might be associated with some persistent small reduction of control.
As expected, the number of patients with adverse reactions was low in both groups and, apart from the predictable oropharyngeal pain possibly related to the regular use of inhaled steroids, no other diff erences between groups were recorded, suggesting that safety is not an issue in considerations of the two alternative therapies, at least from a 1-year perspective. In particular, the use of a less intensive regimen in the as-needed budesonide and formoterol group did not result in a lower risk of adverse events compared with the regular budesonide and formoterol group.
The study had some limitations. Two centres (Genova and Cava dè Tirreni) that had initially agreed to participate in the study later withdrew their willingness to participate because of logistical or local reasons. Therefore, no patients from these centres were enrolled, randomised, or included in the analysis. Furthermore, owing to the limited budget, monitoring of the centres was mainly 
Systematic review
We systematically searched Medline to identify trials of single inhaler maintenance and reliever therapy (SMART) and rescue or as-needed medication in asthma, using the search terms: ("single inhaler", "Symbicort", "Seretide", "Advair", "Viani", "Fostair", or "Clenil Forte") OR ("inhaled corticosteroid", "ICS", "fl uticasone", "FP", "Flixotide", "budesonide", "BUD", "Pulmicort", "beclomethasone", or "Becotide") AND ("long acting beta agonist", "betaagonist", "LABA", "salmeterol", "Serevent", "formoterol", "Oxis", "Foradil", or "Atimos"). We began our search before we designed the study or wrote the protocol, and we searched for articles published from Jan 1, 1950, until Aug 31, 2014, with at least the abstract written in English. We supplemented our Medline search with hand-searches of respiratory journals and meeting abstracts. Of the complete list of references obtained, we selected those relevant to our study, including those about rescue inhaled corticosteroid and longacting β 2 agonist combinations in a single inhaler for mild asthma. To the best of our knowledge, our study is the fi rst trial of rescue budesonide and formoterol combination treatment in a single inhaler for moderate asthma. However, we reviewed all 28 original studies of as-needed inhaled corticosteroid and formoterol combinations in a single inhaler for mild asthma and inhaled corticosteroid and formoterol used as SMART therapy for moderate to severe asthma and we have referenced the most important of these in the Article. Previous studies have shown that inhaled as-needed shortacting β 2 agonist and inhaled corticosteroid or inhaled as-needed longacting β 2 agonist and inhaled corticosteroid combination were eff ective in controlling intermittent or mild asthma, respectively, and that the SMART therapy was more eff ective than regular longacting β 2 agonist and inhaled corticosteroid therapy in moderate to severe asthma.
Interpretation
Current guidelines recommend regular inhaled longacting β 2 agonist and inhaled corticosteroid plus as-needed symptom-driven therapy with rapid-acting β 2 agonists or inhaled corticosteroid and formoterol for the treatment of moderate asthma not controlled by regular inhaled corticosteroids. In this study, we investigated whether a simpler asneeded symptom-driven budesonide and formoterol combination would be as eff ective as regular budesonide and formoterol plus as-needed terbutaline. The fi ndings of our trial confi rm guideline recommendations by showing that the as-needed inhaled therapy is less eff ective than the regular treatment in patients with moderate asthma not controlled by inhaled corticosteroids alone or adequately controlled by longacting β 2 agonist and inhaled corticosteroid combination treatment. However, because the diff erences were small and the level of control remained above that of partially controlled asthma, 1, 23 we speculate that in recommending the regular combination treatment according to guidelines, the results of this study could be discussed with the individual patient.
investigators (listed in the appendix), analysed by PMo and MPa (CROS NT, Verona, Italy), who also contributed to the study design and to the statistical analysis. NS, PMa, PP, MS, SN, IF, GB, SB, MC, MPFB, AS, and MA recruited the patients and contributed to the study design. MPl did the laboratory analyses. The fi rst draft of the report was written by AP and LMF, assisted by BM and BB. All authors discussed and approved all drafts of the report and agreed to submit it for publication. All authors had access to all the data and vouch for the accuracy of the reported data and for the fi delity of this report to the study protocol.
done via teleconferences or the internet and not through direct site visits as is usually done in pharmaceutically sponsored randomised clinical trials. Moreover, the use of paper diary cards was a limitation for the completeness of the data related to peak expiratory fl ow or symptoms. This problem is well known in clinical research and electronic patient-reported outcomes are generally used to limit this problem. However, budget restrictions did not allow us to use this approach.
In conclusion, our results show that as-needed budesonide and formoterol is inferior to regular budesonide and formoterol plus as-needed terbutaline in preventing treatment failure and in maintaining asthma control. However, because the diff erences were small and the level of control remained above that of partially controlled asthma, 1, 23 we speculate that in recommending the regular combination treatment according to guidelines, the results of this study could be discussed with the individual patient. The regular treatment approach could be especially strongly recommended to female patients and to those with a substantial smoking history who have a raised risk of loss of asthma control with as-needed combination treatment. 28 Other patients that in our study had a lower risk of treatment failure could be presented with the advantages of as-needed treatment (convenience, lower cumulative dose of drugs, and potential long-term safety) and could weigh these up against the disadvantages (lower level of asthma control with occasional nocturnal awakening, and increased use of rescue medication).
